Dr Benedict Broennimann joins Company in phase of high growth

Baar (Zug), Switzerland, December 22, 2011 /PR Newswire/ - Waegener is pleased to announce Dr Benedict Broennimann MD as Chief Medical Officer.

Since its establishment in 2003 Waegener has been focusing on research in the field of bioheat transfer technology and applications to achieve significant reduction of inflammation, swelling and pain with a predictable and successful outcome.

Dr Broennimann has been appointed as Chief Medical Officer at Waegener. “Waegener’s technology is the perfect answer to an age-old medical problem: how to control the micro metabolism after injury, trauma or major surgery. The platform that has been developed and perfected by Waegener provides key answers for the orthopedic world as well for other indications. Our medical division with basic and applied research continues to ensure safety and further enhanced patient satisfaction. Our cTreatment applications platform will address the day to day challenges in new medical areas.” Dr. Bennedict Broennimann continues. ”We have strong research programs and studies in place and these will support Waegener in obtaining market leadership”

Mr Levi Dewaegenaere, CEO and founder of Waegener: “With Dr. Broenniman on board Waegener builds further credence to its research and development foundation. He brings significant expertise in research and attracting research partners to finally turn scientific results into medical business focused solutions. We are extremely pleased.”

Chief Commercial Officer, Mr Wout van Loon and co-founder of Waegener continues: “We welcome Dr. Broennimann in our team and with his expertise and background our cTreatment foundation will benefit from an accelerated growth path in several medical solution areas. Precisely while the Company is in a large phase of growth, the conversion of our cTreatment technological platform to the medical need of providing bioheat transfer treatments to our targeted markets is becoming paramount and will lead to a shift in the medical industry. Dr. Broennimann will support our board to contribute to the right choices in the medical field and solutions for our valued patients.“

Dr. Broennimann was Senior Partner at Rosewall Ventures Ltd, an international life sciences engineering company. Prior to that, he was the President and CEO of Leman Cardiovascular SA, a company that develops a novel design of biological heart valve prosthesis and of Hancock Jaffe Laboratories Inc., a biological heart valve manufacturer, Irvine California. While at SmithKlineBeecham (now GlaxoSmithKline), he was the deputy medical director for over eight years.

###

For more information, please contact Pieter van der Poel, Marketing Director at pietervdp@waegener.com or via +41 79 903 69 90.

###

Waegener® is an international medical research and development company predominantly focused on fast track recovery and rehabilitation after traumas and is based in Switzerland. During the last nine years Waegener® developed a range of cTreatments® as a platform to provide specific, protocoled solutions for indications where controlling the inflammation within the optimal ranges, pain and swelling management is vital for fast and total recovery.

Thanks to cTreatment® for orthopedics and trauma indications and trained cTreatment® medical staff, patients recover much faster • Waegener® stands for extensive medical research with medical professionals and • research centers in orthopedics and sports • medicine to offer the best treatments to achieve your objectives in a medication-free • environment.

Headquartered in Baar (Zug), Switzerland, and with subsidiaries in Austria, Belgium and Turkey, Waegener’s employees are dedicated to continuously improving professional sports as well as health care practices. Waegener invests substantially in clinical research and studies, quality and safety, global expansion and the development of new cTreatments®.